IGO's performance for the third quarter of FY24 was marked by decreased product sales and lower lithium prices.

The quarter saw an EBITDA loss of $15 million, mainly due to reduced spodumene sales and prices at the Greenbushes operation.

Underlying free cash flow surged to $79 million, a 182% increase, showcasing resilient financial management.

CEO Ivan Vella highlighted the impact of the subdued nickel and lithium markets on performance. He mentioned the positive trend of improving spodumene prices and the sale of 200kt of spodumene concentrate post-quarter.